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a b s t r a c t
The intermolecular cycloaddition of pyrazinone precursors with alkyne substrates was evaluated. The
resulting regioisomeric [2.2.2]-diketopiperazine alkene cycloadducts were diverted into 2-pyridone
products through cycloreversion of the [2.2.2]-bicyclic intermediates. New insights into the regioselectiv-
ity of pyrazinone azadiene Diels–Alder reactions as well as cycloreversion reactivity were revealed in this
study. Synthetic sequences using this [4+2]/r[4+2] strategy were determined that can produce predom-
inantly the 3,5-disubstituted 2-pyridone alkaloid structures; pyridones featuring the 3,4-substitution
pattern are observed as the minor regioisomeric products.
 2015 Elsevier Ltd. All rights reserved.
Aristolochia manshuriensis is a vining plant with a history of use
in Traditional Chinese Medicine that traces to the 3rd century BCE.1
A. manshuriensis was most widely distributed for purported anti-
inflammatory and diuretic properties, although the most abundant
metabolites, aristolochic acids and structurally-related ester and
amide derivatives, are highly nephrotoxic and carcinogenic.2
Recent efforts have sought to identify constituents in the plant that
possess anti-inflammatory activity and evaluate these metabolites
for cytotoxicity.3 Aristopyridinone A4 (1), a 2-pyridone alkaloid
that does not share the phenanthrene core of the aristolochic acids,
was revealed from renewed isolation efforts, although an insuffi-
cient amount was isolated in order to determine if 1 possessed
anti-inflammatory activity.5
We recently developed a general synthetic method for the con-
struction of 2-pyridone derivatives via cycloaddition of pyrazinone
intermediates and subsequent cycloreversion of the intermediate
[2.2.2]-diazabicycloalkene cycloadduct.6 These preliminary efforts
focused primarily on intramolecular pyrazinone Diels–Alder reac-
tions, where cycloaddition regiochemistry was not assessed. We
viewed 1 as an instructive disubstituted 2-pyridone model in
which to explore the extension of this synthetic strategy to include
an intermolecular Diels–Alder/retro-Diels–Alder process. The 2-
pyridone core is a medicinally privileged scaffold and we predicted
that a synthesis directed toward 1 would provide material to
assess the bioactivity and also prove useful in the construction of
other 2-pyridone-containing molecules.7
Our approach toward pyridone 1 is outlined below (Scheme 1).
We anticipated that the requisite Diels–Alder precursor could be
prepared by aldol condensation of the differentially-protected gly-
cine-derived diketopiperazine8 (DKP) 3 with arylacetaldehyde 2
followed by alkene isomerization of the exocyclic alkene to give
the necessary endocyclic azadiene apparent in pyrazinone 4.
Diels–Alder cycloaddition with a suitable alkyne substrate would
afford the regioisomeric intermediate [2.2.2]-bicyclic adducts 5a
and 5b. The cycloadducts could deliver the 3,4- and 3,5-disubsti-
tuted pyridones 6a and 6b following cycloreversion and selective
extrusion of one lactam bridge (illustrated as the lactim ether).
Final O- and N-deprotection of the aryl ether and dimethoxybenzyl
residues in isomer 6a as well as any necessary functionalization to
reveal the hydroxymethyl at C4 of the pyridone would complete
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aristopyridinone A. At the time we initiated this study, there were
insufficient data to reliably predict which regioisomeric cycload-
duct 5a or 5b would dominate. Because pyrazinones (e.g., 4) are
reactive with both electron-rich and electron-deficient dieneo-
philes, we anticipated that we could explore different electronic
properties of the alkyne dieneophile where the substituent would
be either an electron-donating or electron withdrawing group. In
this way, we envisioned potential control of regioselection in the
Diels–Alder event.
In order to validate our general synthetic plan, we first initiated
a model sequence starting with DKP 3 and benzaldehyde
(Scheme 2). The aldol condensation was completed in a three-step
operation that involved enolization, aldol addition, acetylation, and
elimination of the derived b-acetoxy derivative with DBU to give 7.
Based on our experience with aldol condensations with DKP sub-
strates, we expected DKP alkylidene intermediate 7 to isomerize
under the basic elimination reaction conditions (DBU) to the endo-
cyclic alkene 8.9 We were somewhat surprised that we did not
observe pyrazinone 8 directly from the elimination reaction. The
equilibrium between 7 and 8 is operational as evidenced by
production of cycloadducts 9a and 9b on heating DKP 7 with
DBU in the presence of propargyl alcohol. Heating with DBU in
the absence of propargyl alcohol returned only starting material
DKP 7. We can thus conclude that the exocyclic alkene in 7 is ther-
modynamically more favorable than the isomeric pyrazinone 8.
Cycloadducts 9a and 9b were produced as an inseparable mix-
ture (ratio 1:3) favoring 9b. Cleavage of the lactim O-methyl ether
with KI in AcOH (110 C) provided lactams 10a and 10b, which
could be separated by chromatography. Lactam activation and
cycloreversion were accomplished on major isomer 10b on heating
(110 C) with Ac2O and pyridine to afford the 3,5-substituted
pyridone 11 (97% yield). Our initial communication on the
cycloreversion of [2.2.2]-diketopiperazine alkene substrates to give
2-pyridone products employed microwave heating (max. temp
200 C).6 The modified thermolysis conditions reported in this
Letter are an improvement in efficiency and employ more manage-
able temperatures for cycloreversion (110 C).
The synthesis of pyridone 11 validated our general strategy,
although we wanted to determine cycloaddition reaction condi-
tions that would reverse the regioselectivity and ultimately pro-
vide access to pyridones with 3,4-substitution as the major
product, the structural pattern present in aristopyridinone A (1).
Toward this end, a modified aldol condensation sequence was
performed with 4-methoxyphenylacetaldehyde (2) and could deli-
ver pyrazinone 4 in one reaction vessel (Scheme 3). Because
pyrazinone 4 is somewhat oxygen-sensitive and decomposes on
silica gel, in practice we found it more convenient to isolate and
purify the intermediate b-acetoxy adduct 12. As needed, reserves
of intermediate 12 were converted to pyrazinone 4 by elimination
of the b-acetoxy residue and alkene isomerization with DBU. The
intermediate exocyclic alkene product was not observed in this
sequence and the equilibrium appears to favor pyrazinone 4.
The cycloaddition of pyrazinone 4, which was used directly
without purification, was explored with three electronically dis-
tinct dieneophiles. Using ethyl propiolate, a mixture of cycload-
ducts 13a and 13b was obtained in a 1:2 ratio (63% combined
yield). In agreement with our model system, cycloaddition of 4
with propargyl alcohol afforded adducts 14a and 14b (1:4 ratio,
78% combined yield). The b-acetoxy intermediate 12 was used asScheme 2. Pyridone synthesis model study.
Scheme 3. Preparation and cycloaddition of pyrazinone intermediate.
Scheme 1. Synthesis plan toward 3,4- and 3,5-disubstituted 2-pyridones.
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the starting material for this sequence; acetate elimination, iso-
merization, and Diels–Alder cycloaddition with propargyl alcohol
were accomplished in domino fashion in the same reaction vessel.
The dominant regioisomer possessed 3,5-substitution for the
cycloaddition with both propiolate and propargyl alcohol. Methyl
2-nitroacrylate can be used as a synthetic equivalent of propiolate
that possesses the opposite electronic properties and is often an
effective tool in reversing cycloaddition regioselectivity.10 In our
hands, the nitroacrylate was more reactive and cycloaddition with
pyrazinone 4 was achieved near ambient temperatures; however,
we observed little influence on regioselection and an approximate
1:1 mixture of 15a and 15b was obtained (56% combined yield).
We decided to move forward toward the cycloreversion with
13a and 13b (1:2 ratio), the cycloadducts derived from ethyl propi-
olate (Scheme 4). Toward this end, the lactim O-methyl ether was
cleaved with KI in AcOH (110 C) to give lactams 16a and 16b. We
were unable to effectively separate isomers by chromatography
and the mixture (1:2 ratio) was submitted to the reaction condi-
tions that promote cycloreversion (Ac2O, pyr, 110 C). Isomers
16a and 16b behaved differently under the reaction conditions
and products 19 and 20 were afforded (in 12% and 64% yield).
The 3,5-disubstituted pyridone 20 is the result of cycloreversion
of 16b via the derived activated intermediate 17b. Formation of
the 3,4,6-trisubstituted pyridone 19 from 16a can be explained
by N-C3 bond cleavage, followed by loss of the C6-proton. The
divergent reaction pathways for isomers 16a and 16b are intrigu-
ing and we see two possible explanations for this differing
reactivity.
The observed rearrangement of 16a (in preference to retrograde
Diels–Alder) suggests a highly asynchronous transition state for
the thermolysis. In isomer 16a the bridgehead proton is doubly
activated by both the vinylogous ester at C4 and the imide extend-
ing from C6. As ionization of the N-C3 bond begins, the geometric
constraint of the [2.2.2]-bicyclo bridge relaxes and the C6-bridge-
head proton becomes aligned for deprotonation. Intermediate 18
illustrates complete ionization of the N-C3, although partial ioniza-
tion may be sufficient to permit deprotonation at C6. If intermediate
18 is operational, the thermodynamic acidity of the C6 proton
would be very high (<10 pKa) and enolization would be rapid.
Alternatively, ionization of N-C3 bond in the isomeric intermediate
17b might be destabilized by developing adjacent electropositive
charges (from the b-carbon of the unsaturated ester). This would
potentially shift the reaction pathway toward cycloreversion and
explain why the 3,5-disubstituted pyridone 20 is the observed pro-
duct with isomer 17b. The DMB protecting group provides useful
protection of the pyridone N–H throughout our sequence. We
found that the DMB group is most effectively removed under acidic
conditions as demonstrated by the conversion of pyridone 20 into
21 (TFA, CH2Cl2, Et3SiH, 130 C lx, 30 min, 99% yield).
The thermolysis reaction of 16a and 16b revealed that an elec-
tron withdrawing group at C4 of the [2.2.2]-diketopiperazine
alkene intermediate (such as 16a) will not undergo cycloreversion.
We performed the analogous sequence starting from cycloadducts
14a and 14b (ca. 1:4 ratio), which bear hydroxymethyl substitution
at the alkene (Scheme 5). Cycloreversion of the lactam intermedi-
ates derived from 14a and 14b occurred on both isomeric sub-
strates and afforded the 3,4- and 3,5-pyridones 22a and 22b.
Separation of the isomers was accomplished after removal of the
acetoxy residue (K2CO3, MeOH) gave products 23a and 23b in
28% and 53% isolated yields.
Formation of 23a and 23b demonstrates that cycloreversion is
effective with hydroxymethyl (or acetoxymethyl) substitution on
the derived intermediate [2.2.2]-diazabicyclic structure. Accord-
ingly, this reaction sequence offers a method to access either 3,4-
or 3,5-substituted pyridone products from the corresponding
regioisomeric [2.2.2]-diazabicyclic cycloadducts. The limitations
of this chemistry (at least with the dieneophiles explored in this
study) show that construction of 3,5-disubstituted 2-pyridone
products is the major product and 3,4-disubstituted products are
afforded as minor regioisomeric products. Although intermediate
23a could potentially be converted to aristopyridinone A (1) in a
few operations, in order to execute an efficient synthesis an alter-
native and more selective route toward 1 is warranted.
In summary, we have revealed a method to prepare 2-pyridones
with a synthetic sequence that intercepts an intermolecular
pyrazinone [4+2] cycloaddition, followed by cycloreversion of the
derived intermediate [2.2.2]-bicycloalkene adducts. The reaction
conditions employed for cycloreversion (Ac2O, pyr, 110 C) are
more expeditious and easier to execute than the conditions previ-
ously employed. We gained new insight into both the cycloaddi-
tion and cycloreversion operations. In particular, we revealed
that propargyl alcohol and propiolate give the same dominant
regioisomer for cycloaddition (leading to 3,5-disubstituted pyri-
dones). This result suggests that the regioselectivity in the cycload-
dition of pyrazinone intermediates is not especially responsive to
the electronic nature of the alkyne dieneophile. We also revealed
(a) TFA/CH2Cl2 (1:2), Et3SiH, 130 °C microwave, 30 min (99% yield)
Scheme 4. Divergent reactivity with isomeric [2.2.2]-bicycloadducts.
(a) KI, AcOH, 100 °C (69% yield); (b) Ac2O, pyr, 110 °C (88% yield) 
Scheme 5. Synthesis of 3,4- and 3,5-substituted pyridones.
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that an electron-withdrawing residue at C4 of a [2.2.2]-bicy-
cloalkene cycloadduct promotes a rearrangement in preference to
extrusion of the lactam bridge (cycloreversion). The chemistry
revealed in this synthetic exercise is useful for the construction
of both [2.2.2]-diazabicyclic intermediates and 2-pyridone struc-
tures, in particular, those structures bearing 3,5-substitution.
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